

Nanocarriers Usage for Drug Delivery in Cancer Therapy

Hadi Khodabandehloo,¹ Hamid Zahednasab,² and Asghar Ashrafi Hafez^{3*}

¹Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran

²Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IR Iran

³Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Asghar Ashrafi Hafez, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-2122748001, E-mail: ashrafi@sbmu.ac.ir

Received 2015 August 31; Revised 2015 October 12; Accepted 2016 March 14.

Abstract

Conventional therapeutic agents have displayed significant shortcomings. For this reason, important achievements have effectively made in biotechnology for delivering the therapeutic agents to the site of action, and diminish side effects. Polymeric carriers, micelles, dendrimers, liposomes, solid lipid carriers, gold carriers, viral carriers, nanotubes and magnetic carriers incorporating cytotoxic therapeutics have developed. To improve biological distribution of therapeutic drugs, some modified carriers have designed in optimal size and modified surface area. Delivery of carriers to target cells could be done by passive and active targeting.

Keywords: Carrier, Nanoparticles, Drug Delivery Systems, Neoplasms, Therapeutics

1. Context

Conventional therapeutic agents have distributed non-specifically in body, affecting both target and normal cells. This phenomenon has reduced the efficient dose of the drugs reaching the target cells, then caused suboptimal results due to excessive toxicity (1).

Drug carriers were able to diminish toxicity of the therapeutic agents in neighbor cells and have selectively augmented the amount of drugs accumulated within target cells (2, 3). Although the beneficial effects of carriers have been increasing, some obstacles exist in their implementation for therapeutic purposes. These obstacles include: instability in blood circulation, undesirable bio-distribution, their own toxicity and lack of oral bioavailability (4).

2. Evidence Acquisition

In this review, we have decided to take a glance at the following subjects; first, the types and characteristics of carriers; second, how carriers should develop to improve their therapeutic efficacy?

3. Results

3.1. Delivery Vehicles

Carriers have used in drug delivery systems have consisted of the simplest form of structures with sizes in the nm or μm ranges, made of polymers (polymeric carriers,

micelles or dendrimers), lipids (liposomes), solid lipid carriers, gold carriers, viruses, nanotubes and magnetic carriers (1).

3.1. Polymeric Carriers

Polymeric carriers have composed of natural or synthetic polymers (Figure 1). Depending on the methods used for preparation of polymeric carriers, drugs could be entrapped within the polymer or attached to the carrier matrix leading to the formation of nano/microcapsules and nano/microspheres, respectively (5). In our study, we have reported the synthesis of 166Ho-Poly lactic acid microspheres with solvent evaporation technique (6).

3.2. Polymeric Micelles

Micelles have made of amphiphilic block copolymers (Figure 1). The hydrophobic region has served as a reservoir for poorly water soluble drugs, whereas the hydrophilic region has stabilized the hydrophobic core, and then made the conjugate water soluble (7).

Polymeric micelles, due to their ability in loading of lipophilic molecules into the hydrophobic core, have used to solubilize and deliver poorly water-soluble drugs (8).

Up to now, seven clinical trials using polymeric micelle anticancer drug-targeting systems have done in clinical studies in different phases. Tumor targeting, solubilization of water-insoluble drugs and circumvention of multi-drug resistance (MDR) were the objective of these trials with various combination of drugs (9, 10).




Figure 1. Different Types of Nanocarriers Have Used for Drug Delivery

3.3. Dendrimers

Dendrimers have highly branched macromolecules, composed of several extremely branched monomers that emerge radially from the central core (Figure 1). The modifiable surface characteristics of dendrimers enable them to be simultaneously conjugated with several molecules such as imaging contrast agents, ligands or therapeutic drugs, and hence have created a multifunctional drug delivery system (11).

Due to the increasing use of dendrimers in biomedical applications, the biological properties of dendrimers were important. Cationic dendrimers were usually hemolytic

and cytotoxic. Their toxicity was generation-dependent and has increased with the number of the surface groups (12). There were indications that cationic dendrimers have cleared rapidly from the blood stream upon the intravenous or intraperitoneal injection. Anionic dendrimers had longer circulation time. Their clearance rate was generation-dependent, and lower generation would have longer circulation time (13). Note that the anionic dendrimers containing carboxylate group were not cytotoxic in the board range of concentrations (14).

Flexibility in the dendrimer families was due to the fact that the surface, internal cavity and dendrimer core could

change for different applications. Most of the applications of the dendrimers have based on their multifunctional structure and presence of internal cavities. These properties make the dendrimers suitable for diverse technological applications such as biomedical and industrial applications (15). Such applications were: in vitro diagnostics (15), as a contrast agent in MRI (16), delivery of drugs (17), in boron neutron capture therapy (BNCT) (18), as a vector in gene therapy (19), and in photodynamic therapy (PDT) (20).

3.4. Liposomes

Liposomes have known as spherical lipid vesicles that could be formed via the accumulation of lipids interacting with each other in an energetically favorable manner (Figure 1). The liposome bilayer could be formed from synthetic or natural phospholipids. The important physical and chemical properties of a liposome, including permeability, charge density and steric hindrance, have based on its constituent phospholipids (21).

The use of liposomes as a vehicle in drug delivery systems had several advantages including diverse range of morphologies, compositions, ability to envelope and protect many types of therapeutic biomolecules, lack of immunologic response, low cost and their differential release characteristics (22).

Myocet and Doxil were the first-approved liposome-based drugs for cancer treatment. Currently, twenty-one liposome-based drugs have been testing by clinical trials (23-25).

3.5. Solid Lipid Carriers

Solid lipid carriers (SLCs), have also referred as lipospheres or solid lipid nanospheres, were solid at human physiological temperature and had a diameter of 50 - 100 nm (Figure 1). The SLCs could be made from diverse range of lipids including mono-, di- and triacylglycerols, fatty acids, waxes and combination of these materials. The SLCs could be formed by replacing oil with solid lipid in an oil and water (O/W) emulsion. Also, the SLCs were biodegradable and biocompatible and could be used in human because of their reduced cytotoxicity (26). These carriers have formed a lipophilic matrix which enabled the drug to load onto it. The important factors have been affecting drugs loading into the SLC matrix were solubility of drug in lipid (drug must be lipophilic), physical and chemical properties of lipid or mixture of lipids, crystalline properties of lipids in biological temperature, and polymorphic form of the lipids. The SLCs have been investigated for delivery of various anticancer drugs with promising results in mouse preclinical phases. Specifically, it has been shown that the

SLCs could help to overcome multi-drug resistance problems in cancer therapy (26).

Recently, Kaur and Slavcev have reported the pre-clinical development of a docetaxel nanocarriers against prostate specific antigen (27).

3.6. Gold Carriers

Gold carriers have consisted of a core of gold atoms (Figure 1) that could be functionalized through the addition of monolayer of thiol (SH)-containing groups (28). Gold carriers could be synthesized in the presence of thiol-containing groups which form a layer around the gold atoms and by considering the stoichiometric ratio of gold to thiol (gold/thiol) utilizing NaBH₄ for reduction of AuCl₄-salts (29). Research studies have shown that gold carriers were not cytotoxic at cellular levels in a number of human cell lines (30). A recent study has confirmed that PEGylated gold carriers (10 - 30 nm) have not been able to cross from human placenta within 6 hours, and could be used to restrict drug delivery to mother while preventing teratogenic effects on the fetus (31).

The first clinical trial with gold carriers have done in 2009, in which a 27-nm citrate-coated gold carriers (CYT-6091) bound with thiolated PEG and TNF- α have employed in patients with solid organ cancers (32).

3.7. Magnetic Carriers

The most unique feature of magnetic carriers (Figure 1) was their reaction to a magnetic force. Magnetic carriers have injected into the bloodstream, and then magnetic fields have focused over the target site (33). The first report of a clinical trial has appeared in 1996 (34), in which non-covalent interactions of epirubicin have used for binding to 100 nm magnetic carriers, and permanent high-energy magnets have used to target tumor tissues. Moreover, magnetic carriers have attracted attentions because of their potential as contrast agents for magnetic resonance imaging (MRI) and heating mediators (hyperthermia) for cancer therapy (35).

3.8. Albumin Carriers

Albumin has been widely employed as a drug carrier. Albumin would be soluble in both water and ethanol. Since albumin has presented in human body, it was non-toxic, and well-tolerated by the immune system. Additionally, albumin due to its higher half-life in blood circulation, had favorable pharmacokinetics and was an interesting drug carrier for passive targeting (36).

Abraxane, the chemotherapy drug paclitaxel has attached to an albumin carrier, was the first drug based on

an albumin carrier. Abraxane had advantages over paclitaxel including increased half-life in the circulation and lack of hypersensitivity (37). It has thought that Abraxane has transported into tumor cells by osteonectin or secreted acidic protein rich in cysteine (SPARC) (38).

3.9. Viral Carriers

Viruses naturally and with great efficiency have infected and delivered their genetic contents to host cells (Figure 1). Therefore, viruses have increasingly drawn attractions as favorable carriers for drug delivery. Virus-like particles were genome-free counterparts of viral carriers, and actually could classify as a subclass of viral carriers. Viral carriers, derived from plants and bacteria, were invaluable carriers, because they were not only biocompatible and biodegradable, but also they were non-toxic and non-infectious in humans and other mammals (39). Viral carriers have produced by nature, could regard as one of the advanced drug delivery systems due to their highly symmetrical structure (40, 41). The basic structure of viral carriers could be manipulated in such a way that its internal cavity has filled with drug molecules, imaging reagents, whereas the external surface could be decorated with targeting ligands (42).

3.10. Carbon Carriers

Carbon nanotubes (CNTs) were members of the fullerene structural family composed of benzene rings rolled-up into a tubular structure (Figure 1). CNTs had nanometric dimensions, and they have fallen into two groups based on their structure; single-walled (SWNTs), which consisted of one layer of cylinder graphene and multi-walled (MWNTs) containing multiple concentric graphene layers. The SWNTs had a diameter about 0.4 - 2 nm and length of 20 - 100 nm, while MWNTs were larger in size with a diameter in the range of 1.4 - 100 nm and length from 1 to several μm (43).

The organized structure, ultralight weight, high mechanical strength, high electrical conductivity, high thermal conductivity, metallic or semi-metallic behavior and high surface area (43) were the properties that have caused CNTs to be a suitable carrier in drug delivery system. Combination of these properties made CNT a unique material for diverse applications such as biomedical interventions (44). Increasing interests in use of these properties have made these materials a good candidate for various applications including construction of biosensors for detection of genetic disorders or other molecular abnormalities, substances for cell growth in tissue regeneration, and in drug delivery systems for a broad range of diagnostic and therapeutic agents (43).

Non-functional CNTs were intrinsically hydrophobic. Therefore, the main obstacle in the utilization of CNTs in biology and medicinal chemistry was the lack of solubility in most compatible solvents with biological milieu. To overcome this problem, modification of a CNT surface has mediated by adsorption, electrostatic interaction or covalent bonding of different molecules that render them hydrophilic. These modifications have improved water solubility of the CNTs and their biocompatibility profile. Moreover, due to these modifications, the aggregation of individual tubes through van der Waals forces has reduced (43).

In a recent clinical trial study, Jun Yan reported that CNTs had no toxic side effects on the human body after injection into the tissues around the tumor (45).

3.11. Advantages of Nanoscale Drug Delivery Systems

Biological substances have cleared from the blood stream according to their size. Small particles (1 - 30 nm) were rapidly cleared by the kidney. Carriers having size larger than 30 nm have cleared by reticuloendothelial system (RES), which included macrophages located in the liver and spleen (46). Clearance was also dependent on endothelial fenestral size (46). The size of fenestrae was pretty variable. It was difficult to determine the efficacy and toxicity of drug carriers in different individuals, because age, sex and genetic predisposition affect rate of their clearance (47). Whether nanocarriers would take up by the macrophages or not, depended on opsonization by the innate immune system (48). Surface properties of nanocarriers could affect rate of their clearance by RES. A useful method that has helped large particles escape from opsonization has developed in Rutgers university in the 1960s (49); In a process that called PEGylation, a polymer, polyethylene glycol (PEG; $[\text{CH}_2\text{CH}_2\text{O}]_n$), has conjugated to a drug carrier.

3.12. Size and Surface Properties of Carriers

In order to be effectively delivered towards the target tissues, carriers should be able to remain in the blood circulation for adequate duration of time. Unmodified conventional carriers have used in drug delivery systems have cleared from blood stream by RES depending on their size and surface characteristics (50). Therefore, the fate of injected carriers could be controlled by modulation of their size as well as surface characteristics.

3.13. Particle Size

Particle size was the most important characteristics of carrier systems. It has determined the in vivo distribution, biological fate, toxicity and the targeting ability of carrier

systems (51). The size of nanoparticles have used in drug delivery systems should be large enough to prevent from leakage into the blood capillaries. On the other hand, it should be small enough to escape from macrophages located in RES (1). In our study, microspheres have synthesized with a diameter of 5 - 10 μm without any leakage to the other organs (6).

3.14. Surface Properties of Carriers

Apart from the size of carriers, the surface properties of carriers were another important factor affecting their half-life and fate in blood stream. Surface hydrophobicity of carriers has determined the opsonization. Surface non-modified carriers have opsonized and cleared by the macrophage of RES. Hence, to prolong the circulation of carriers in vivo and to increase the likelihood of the success in drug targeting by carriers, it was necessary to minimize the opsonization. This was possible with two procedures including surface coating of carriers with hydrophilic polymers such as PEG, and construction of carriers from biodegradable block copolymers with hydrophilic and hydrophobic domains (7, 52).

3.15. Types of Targeted Drug Delivery

As outlined above, targeted drug delivery not only has increased the therapeutic effect of drugs, but also, diminished the cytotoxicity to adjacent cells. For the achievement of such conditions, passive targeting and active targeting, have both used.

3.15.1. Passive Targeting

Passive targeting was the preferential accumulation of therapeutic agents in target tissues according to physico-chemical or pharmacological factors of the disease. For example, in cancer treatment, Because of higher metabolic demand, cancer cells were required for neovascularization near the tumor mass to supply the oxygen and nutrients (53). This has resulted in disorganized tumor vessels with numerous pores showing enlarged gap junctions between endothelial cells (53). These unique characteristic of tumor vessels has called enhanced permeability and retention effect, have enabled the macromolecules such as nanocarriers to selectively accumulate in a tumor tissue (3).

Another example of passive targeting was acidic environment of tumor cells. A tumor microenvironment would often be hypoxic; Lack of oxygen has caused the tumor cells use glycolysis pathway to get extra energy leaving the extracellular microenvironment acidic (54). Some sorts of pH-sensitive liposomes have designed so that they are stable in physiologic pH but they have disintegrated, and release the drug into targeted tissues that have pH less

than physiologic one, such as microenvironment of tumor cells (55).

3.15.2. Active Targeting

Passive targeting with carriers, however, encountered multiple obstacles included: mucosal barriers, nonspecific uptake of the particle and non-specific delivery of the drug (56). Attachment of a ligand or antibody to the carriers, active targeting, was an approach suggested to diminish these restrictions (2).

4. Conclusions

Thanks to complex cellular network in body, delivery of drug to its specific site has been a difficult task. On the basis of the evidence summarized in this review, targeted drug delivery has been coming forward as one of the advanced technique in the field of nanomedicine in the diagnosis and treatment of diseases. Advancement in the field of nanomedicine has been increasing, such that multifunctional carriers that allowed concurrent imaging and therapy have been developed.

Acknowledgments

We have benefited from diverse number of valuable articles for preparation of this manuscript. Therefore, we have appreciated all scientists and researchers in this field.

Footnotes

Authors' Contribution: All authors have collaborated in writing of this article. Hamid Zahednasab have designed the study and contributed to the majority part of the literature review. Asghar Ashrafi Hafez have participated in writing-up and overall revision process. Finally all authors have read and approved the manuscript.

Conflict of Interests: The authors had no conflict of interest in this review article.

Financial Disclosure: None declared.

Funding/Support: None declared.

References

1. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. *Clin Cancer Res.* 2008;**14**(5):1310-6. doi: [10.1158/1078-0432.CCR-07-1441](https://doi.org/10.1158/1078-0432.CCR-07-1441). [PubMed: [18316549](https://pubmed.ncbi.nlm.nih.gov/18316549/)].
2. Allen TM. Ligand-targeted therapeutics in anticancer therapy. *Nat Rev Cancer.* 2002;**2**(10):750-63. doi: [10.1038/nrc903](https://doi.org/10.1038/nrc903). [PubMed: [12360278](https://pubmed.ncbi.nlm.nih.gov/12360278/)].
3. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. *Adv Enzyme Regul.* 2001;**41**:189-207. [PubMed: [11384745](https://pubmed.ncbi.nlm.nih.gov/11384745/)].

4. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. *Am J Respir Crit Care Med*. 2005;**172**(12):1487-90. doi: [10.1164/rccm.200504-613PP](https://doi.org/10.1164/rccm.200504-613PP). [PubMed: [16151040](https://pubmed.ncbi.nlm.nih.gov/16151040/)].
5. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. *Biol Pharm Bull*. 2006;**29**(9):1790-8. [PubMed: [16946487](https://pubmed.ncbi.nlm.nih.gov/16946487/)].
6. Yavari K, Khodabandehloo H, Taghikhani M, Mazidi M, Kalantari B, Asl RS, et al. Development of 166Ho Poly Lactic Acid Microspheres for Radiosynovectomy. *J Pharm Pharmacol*. 2013;**1**:25-35.
7. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. *J Pharm Sci*. 2003;**92**(7):1343-55. doi: [10.1002/jps.10397](https://doi.org/10.1002/jps.10397). [PubMed: [12820139](https://pubmed.ncbi.nlm.nih.gov/12820139/)].
8. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. *J Pharmacol Toxicol Methods*. 2000;**44**(1):235-49. [PubMed: [11274893](https://pubmed.ncbi.nlm.nih.gov/11274893/)].
9. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. *Expert Opin Drug Deliv*. 2010;**7**(2):145-58. doi: [10.1517/17425240903436479](https://doi.org/10.1517/17425240903436479). [PubMed: [20095939](https://pubmed.ncbi.nlm.nih.gov/20095939/)].
10. Yokoyama M. Clinical Applications of Polymeric Micelle Carrier Systems in Chemotherapy and Image Diagnosis of Solid Tumors. *J Expe Clin Med*. 2011;**3**(4):151-8. doi: [10.1016/j.jecm.2011.06.002](https://doi.org/10.1016/j.jecm.2011.06.002).
11. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. *Adv Drug Deliv Rev*. 2005;**57**(15):2106-29. doi: [10.1016/j.addr.2005.09.018](https://doi.org/10.1016/j.addr.2005.09.018). [PubMed: [16305813](https://pubmed.ncbi.nlm.nih.gov/16305813/)].
12. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. *J Biomed Mater Res*. 1996;**30**(1):53-65. doi: [10.1002/\(SICI\)1097-4636\(199601\)30:1<t;53::AID-JBM8gt;3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1097-4636(199601)30:1<t;53::AID-JBM8gt;3.0.CO;2-Q). [PubMed: [8788106](https://pubmed.ncbi.nlm.nih.gov/8788106/)].
13. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. *Curr Opin Chem Biol*. 2002;**6**(4):466-71. [PubMed: [12133722](https://pubmed.ncbi.nlm.nih.gov/12133722/)].
14. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers. *J Control Release*. 2000;**65**(1-2):133-48. doi: [10.1016/S0168-3659\(99\)00246-1](https://doi.org/10.1016/S0168-3659(99)00246-1).
15. Klajnert B, Bryszewska M. Dendrimers: properties and applications. *Acta Biochim Pol*. 2001;**48**(1):199-208. [PubMed: [11440170](https://pubmed.ncbi.nlm.nih.gov/11440170/)].
16. Fischer M, Vögtle F. Dendrimers: from design to application—a progress report. *Angewandte Chemie Int Edit*. 1999;**38**(7):884-905.
17. Sigal GB, Mammen M, Dahmann G, Whitesides GM. Polyacrylamides Bearing Pendant α -Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions. *J Am Chem Soc*. 1996;**118**(16):3789-800. doi: [10.1021/ja953729u](https://doi.org/10.1021/ja953729u).
18. Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. *Bioconjug Chem*. 1994;**5**(1):58-66. [PubMed: [8199235](https://pubmed.ncbi.nlm.nih.gov/8199235/)].
19. Haensler J, Szoka FJ. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. *Bioconjug Chem*. 1993;**4**(5):372-9. [PubMed: [8274523](https://pubmed.ncbi.nlm.nih.gov/8274523/)].
20. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic Therapy. *JNCI J Nation Cancer Inst*. 1998;**90**(12):889-905. doi: [10.1093/jnci/90.12.889](https://doi.org/10.1093/jnci/90.12.889).
21. Bawarski WE, Chidlowy S, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. *Nanomed Nanotechnol Biol Med*. 2008;**4**(4):273-82. doi: [10.1016/j.nano.2008.06.002](https://doi.org/10.1016/j.nano.2008.06.002).
22. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. *Eur J Pharm Sci*. 2010;**40**(3):159-70. doi: [10.1016/j.ejps.2010.03.019](https://doi.org/10.1016/j.ejps.2010.03.019). [PubMed: [20359532](https://pubmed.ncbi.nlm.nih.gov/20359532/)].
23. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. *Int J Nanomedicine*. 2012;**7**:49-60. doi: [10.2147/IJN.S26766](https://doi.org/10.2147/IJN.S26766). [PubMed: [22275822](https://pubmed.ncbi.nlm.nih.gov/22275822/)].
24. Fan Y, Zhang Q. Development of liposomal formulations: From concept to clinical investigations. *Asian J Pharm Sci*. 2013;**8**(2):81-7. doi: [10.1016/j.ajps.2013.07.010](https://doi.org/10.1016/j.ajps.2013.07.010).
25. Ming-Kung Y. Clinically-Proven Liposome-Based Drug Delivery: Formulation, Characterization and Therapeutic Efficacy. Open Access Scientific Reports; 2012.
26. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. *Adv Drug Deliv Rev*. 2007;**59**(6):491-504. doi: [10.1016/j.addr.2007.04.008](https://doi.org/10.1016/j.addr.2007.04.008). [PubMed: [17532091](https://pubmed.ncbi.nlm.nih.gov/17532091/)].
27. Kaur T, Slavcev R. Novel Gene Therapy Approaches. Intech; 2013. Solid lipid nanoparticles: tuneable anti-cancer gene/drug delivery systems.
28. Xu ZP, Zeng QH, Lu GQ, Yu A. Inorganic nanoparticles as carriers for efficient cellular delivery. *Chem Engin Sci*. 2006;**61**(3):1027-40.
29. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. *Adv Drug Deliv Rev*. 2008;**60**(11):1307-15. doi: [10.1016/j.addr.2008.03.016](https://doi.org/10.1016/j.addr.2008.03.016). [PubMed: [18555555](https://pubmed.ncbi.nlm.nih.gov/18555555/)].
30. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. *Small*. 2005;**1**(3):325-7. doi: [10.1002/smll.200400093](https://doi.org/10.1002/smll.200400093). [PubMed: [17193451](https://pubmed.ncbi.nlm.nih.gov/17193451/)].
31. Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vahakangas KH. Kinetics of gold nanoparticles in the human placenta. *Reprod Toxicol*. 2008;**26**(2):130-7. doi: [10.1016/j.reprotox.2008.06.008](https://doi.org/10.1016/j.reprotox.2008.06.008). [PubMed: [18638543](https://pubmed.ncbi.nlm.nih.gov/18638543/)].
32. Libutti SK, Paciotti GF, Myer L, Haynes R, Gannon W, Walker M, et al, editors. Results of a completed phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine. ASCO annual meeting proceedings. 2009; p. 3586.
33. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. *Int J Nanomedicine*. 2008;**3**(2):169-80. [PubMed: [18686777](https://pubmed.ncbi.nlm.nih.gov/18686777/)].
34. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. *Cancer Res*. 1996;**56**(20):4686-93. [PubMed: [8840985](https://pubmed.ncbi.nlm.nih.gov/8840985/)].
35. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. *J Biosci Bioeng*. 2005;**100**(1):1-11. doi: [10.1263/jbb.100.1](https://doi.org/10.1263/jbb.100.1). [PubMed: [16233845](https://pubmed.ncbi.nlm.nih.gov/16233845/)].
36. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. *J Control Release*. 2008;**132**(3):171-83. doi: [10.1016/j.jconrel.2008.05.010](https://doi.org/10.1016/j.jconrel.2008.05.010). [PubMed: [18582981](https://pubmed.ncbi.nlm.nih.gov/18582981/)].
37. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. *Adv Drug Deliv Rev*. 2008;**60**(8):876-85. doi: [10.1016/j.addr.2007.08.044](https://doi.org/10.1016/j.addr.2007.08.044). [PubMed: [18423779](https://pubmed.ncbi.nlm.nih.gov/18423779/)].
38. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. *Urol Oncol*. 2008;**26**(1):57-64. doi: [10.1016/j.urolonc.2007.03.015](https://doi.org/10.1016/j.urolonc.2007.03.015). [PubMed: [18190833](https://pubmed.ncbi.nlm.nih.gov/18190833/)].
39. Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. *J Control Release*. 2007;**120**(1-2):41-50. doi: [10.1016/j.jconrel.2007.04.003](https://doi.org/10.1016/j.jconrel.2007.04.003). [PubMed: [17512998](https://pubmed.ncbi.nlm.nih.gov/17512998/)].
40. Agirrezabala X, Velazquez-Muriel JA, Gomez-Puertas P, Scheres SH, Carazo JM, Carrascosa JL. Quasi-atomic model of bacteriophage τ pro-capsid shell: insights into the structure and evolution of a basic fold. *Structure*. 2007;**15**(4):461-72. doi: [10.1016/j.str.2007.03.004](https://doi.org/10.1016/j.str.2007.03.004). [PubMed: [17437718](https://pubmed.ncbi.nlm.nih.gov/17437718/)].
41. Sherman MB, Guenther RH, Tama F, Sit TL, Brooks CL, Mikhailov AM, et al. Removal of divalent cations induces structural transitions in red clover necrotic mosaic virus, revealing a potential mechanism for RNA release. *J Virol*. 2006;**80**(21):10395-406. doi: [10.1128/JVI.01137-06](https://doi.org/10.1128/JVI.01137-06). [PubMed: [16920821](https://pubmed.ncbi.nlm.nih.gov/16920821/)].
42. Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. *Mol Pharm*. 2011;**8**(1):29-43. doi: [10.1021/mp100225y](https://doi.org/10.1021/mp100225y). [PubMed: [21047140](https://pubmed.ncbi.nlm.nih.gov/21047140/)].

43. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. *Adv Drug Deliv Rev.* 2006;**58**(14):1460–70. doi: [10.1016/j.addr.2006.09.015](https://doi.org/10.1016/j.addr.2006.09.015). [PubMed: [17113677](https://pubmed.ncbi.nlm.nih.gov/17113677/)].
44. Bianco A, Kostarelos K, Partidos CD, Prato M. Biomedical applications of functionalised carbon nanotubes. *Chem Commun (Camb).* 2005(5):571–7. doi: [10.1039/b410943k](https://doi.org/10.1039/b410943k). [PubMed: [15672140](https://pubmed.ncbi.nlm.nih.gov/15672140/)].
45. Yan J, Xue F, Chen H, Wu X, Zhang H, Chen G, et al. A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer. *Surg Endosc.* 2014;**28**(12):3315–21. doi: [10.1007/s00464-014-3608-5](https://doi.org/10.1007/s00464-014-3608-5). [PubMed: [24935202](https://pubmed.ncbi.nlm.nih.gov/24935202/)].
46. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. *Eur J Pharm Biopharm.* 2008;**69**(1):1–9. doi: [10.1016/j.ejpb.2007.08.001](https://doi.org/10.1016/j.ejpb.2007.08.001). [PubMed: [17826969](https://pubmed.ncbi.nlm.nih.gov/17826969/)].
47. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. *Toxicol Appl Pharmacol.* 2008;**229**(1):121–34. doi: [10.1016/j.taap.2008.02.007](https://doi.org/10.1016/j.taap.2008.02.007). [PubMed: [18355886](https://pubmed.ncbi.nlm.nih.gov/18355886/)].
48. Owens D3, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *Int J Pharm.* 2006;**307**(1):93–102. doi: [10.1016/j.ijpharm.2005.10.010](https://doi.org/10.1016/j.ijpharm.2005.10.010). [PubMed: [16303268](https://pubmed.ncbi.nlm.nih.gov/16303268/)].
49. Hoffman AS. The origins and evolution of "controlled" drug delivery systems. *J Control Release.* 2008;**132**(3):153–63. doi: [10.1016/j.jconrel.2008.08.012](https://doi.org/10.1016/j.jconrel.2008.08.012). [PubMed: [18817820](https://pubmed.ncbi.nlm.nih.gov/18817820/)].
50. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacol Rev.* 2001;**53**(2):283–318. [PubMed: [11356986](https://pubmed.ncbi.nlm.nih.gov/11356986/)].
51. Mohanraj VJ, Chen Y. Nanoparticles-a review. *Trop J Pharm Res.* 2007;**5**(1):561–73.
52. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. *Clin Pharmacokinet.* 2001;**40**(7):539–51. doi: [10.2165/00003088-200140070-00005](https://doi.org/10.2165/00003088-200140070-00005). [PubMed: [11510630](https://pubmed.ncbi.nlm.nih.gov/11510630/)].
53. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000;**407**(6801):249–57. doi: [10.1038/35025220](https://doi.org/10.1038/35025220). [PubMed: [11001068](https://pubmed.ncbi.nlm.nih.gov/11001068/)].
54. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. *Oncogene.* 2006;**25**(34):4633–46. doi: [10.1038/sj.onc.1209597](https://doi.org/10.1038/sj.onc.1209597). [PubMed: [16892078](https://pubmed.ncbi.nlm.nih.gov/16892078/)].
55. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. *Science.* 1980;**210**(4475):1253–5. [PubMed: [7434025](https://pubmed.ncbi.nlm.nih.gov/7434025/)].
56. Abhilash M. Potential applications of Nanoparticles. *Int J Pharm Bio Sci.* 2010;**1**(1):1–12.